Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial
Nutrients · 2026
DOI: 10.3390/nu18182983 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2026. Verfasst von Samantha Glover und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Dentistry and Dental Public Health, Adams School of Dentistry, University of North Carolina, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Eicosapentaenoic Acid, Dietary Supplements, Docosahexaenoic Acids. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Diet, Physical Activity and Body Composition Core of the Nutrition Obesity Research Center (NORC) at the University of North Carolina at Chapel Hill.
Abstract (Originalsprache)
Background/Objectives: Omega-3 polyunsaturated fatty acids (PUFAs) influence lipid-mediated inflammatory pathways implicated in migraine, yet randomized trial data evaluating biologic effects of omega-3 supplementation in youth with migraine remain limited. This pilot quasi-randomized clinical trial aimed to determine whether 12 weeks of omega-3 PUFA supplementation produces measurable changes in whole-blood EPA and DHA levels in children and adolescents with migraine, and to characterize changes in patient-reported measures of pain, migraine-related disability, and psychological distress.
Methods
We conducted a parallel-group, quasi-randomized, double-blind, placebo-controlled trial in children and adolescents (ages 10–17) with migraine diagnosed per International Classification of Headache Disorders, 3rd edition criteria, recruited from pediatric neurology clinics at two academic medical centers. Of 57 participants allocated 1:1 to daily omega-3 PUFA supplementation (340 mg EPA + 510 mg DHA) or coconut oil placebo for 12 weeks, 44 completed the study and were analyzed. The primary outcome was change in whole-blood omega-3 PUFA index. Secondary outcomes included patient-reported measures of pain intensity, pain interference, migraine-related disability, and psychological distress. Exploratory outcomes included changes in omega-6/omega-3 and arachidonic acid/eicosapentaenoic acid (AA/EPA) ratios. Between-group differences were evaluated using ANCOVA adjusting for baseline values.
Results
Omega-3 supplementation significantly altered lipid biomarker profiles. Compared with placebo, the intervention group demonstrated greater increases in omega-3 PUFA index (adjusted mean difference 1.64; 95% CI 0.94–2.35; p < 0.001) and greater reductions in omega-6/omega-3 ratio (−2.57; 95% CI −4.25 to −0.90; p = 0.003) and AA/EPA ratio (−13.52; 95% CI −21.55 to −5.49; p = 0.002), consistent with the increase in whole-blood omega-3 levels. No significant between-group differences were observed in patient-reported outcomes.
Conclusions
Omega-3 PUFA supplementation significantly altered lipid biomarker profiles in youth with migraine over 12 weeks, supporting a measurable whole-blood EPA + DHA response in this proof-of-concept trial. Future larger-scale trials with longer duration are needed to evaluate clinical effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Dentistry and Dental Public Health, Adams School of Dentistry, University of North Carolina, Chapel Hill, NC 27599, USA.
- Department of Physical Medicine and Rehabilitation, School of Medicine, University of North Carolina, Chapel Hill, NC 27514, USA.
- Department of Nutrition, Gillings School of Global Public Health and School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA.
- Division of Pediatric Neurology, Duke University Medical Center, Durham, NC 27705, USA.
- Department of Neurology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
ORCID-Profile: Samantha Glover, Anne E Sanders, Daisy Zamora, Keturah R Faurot, Kimon Divaris, Steven P Trau, Jaclyn Bain, Jialiu Xie, Thomas Southern, Caroline M Sawicki
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- Diet, Physical Activity and Body Composition Core of the Nutrition Obesity Research Center (NORC) at the University of North Carolina at Chapel Hill
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Glover, S., Sanders, A. E., Zamora, D., Faurot, K. R., Shaikh, S. R., Divaris, K., Werner, K., Trau, S. P., Bain, J., Xie, J., Danze, S., Singh, S., Southern, T., Iskander, J., & Sawicki, C. M. (2026). Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial. Nutrients. https://doi.org/10.3390/nu18182983
Vancouver
Glover S, Sanders AE, Zamora D, Faurot KR, Shaikh SR, Divaris K, et al. Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial. Nutrients. 2026. doi:10.3390/nu18182983
BibTeX
@article{Glover2026,
author = {Glover, Samantha and Sanders, Anne E and Zamora, Daisy and Faurot, Keturah R and Shaikh, Saame Raza and Divaris, Kimon and Werner, Klaus and Trau, Steven P and Bain, Jaclyn and Xie, Jialiu and Danze, Sydney and Singh, Sajan and Southern, Thomas and Iskander, Joseph and Sawicki, Caroline M},
title = {Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18182983}
}
EUVIMED